Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

计划入组 124 人 · 首次发布于 2021 年 10 月 5 日

C3G/Primary IC-MPGN EAP

首次发布于 2021 年 1 月 28 日

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

计划入组 7 人 · 首次发布于 2018 年 10 月 29 日

Glomerulonephritis(Everest Medicines)

BQ-Complex

Gastropylor Complex

HAYATABAD MEDICAL COMPLEX

Pakistan

SALMANIYA MEDICAL COMPLEX

Bahrain

MARDAN MEDICAL COMPLEX

Pakistan

Emerging Therapies Show Promise for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

CDSCO Approves Novartis' Protocol Amendment for Iptacopan Study in Rare Kidney Disorders

Pegcetacoplan Shows Promise in C3G and IC-MPGN Treatment: VALIANT Trial